Dottorato in Fisiopatologia Medica

LITMUS - Liver Investigation: Testing Marker Utility in Steatohepatitis - This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

EPoS - Elucidating Pathways of Steatohepatitis - funded by the European Union's Horizon 2020 Framework Programme under grant agreement no. 634413.

Younes, R. & Bugianesi, E. The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality Curr Hepatology Rep (2018). https://doi.org/10.1007/s11901-018-0422-x

Di Stefano C, Vanni E, Mirabella S, Younes R et al. Risk factors for arterial hypertension after liver transplantation. J Am Soc Hypertens. 2018 Mar;12(3):220-229. Epub 2018 Jan 5

Younes R, Morgando A. Comment on Helicobacter pylori eradication using metronidazole. Minerva Gastroenterol Dietol. 2018 Mar;64(1):96. doi: 10.23736/S1121-421X.17.02418-7

Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018 Feb;68(2):326-334. doi: 10.1016/j.jhep.2017.10.006. 

Younes R, Rosso C, Petta S, Cucco M, et al. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver Int. 2018 Apr;38(4):715-723. doi: 10.1111/liv.13612. Epub 2017 Nov 3.

Younes R, Ponzo P, Marzano A. Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct. Minerva Gastroenterol Dietol. 2017 Dec;63(4):431-434. doi: 10.23736/S1121-421X.17.02323-6

Rosso C., Younes R. et al. Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease. American Association for the Study of Liver Diseases – 20-24 October 2017; Washington – USA

Younes R., Rosso C. et al. Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease. American Association for the Study of Liver Diseases – 20-24 October 2017; Washington – USA

Rosso C., Younes R. et al. Bile Acid Composition Modulates Insulin Resistance In Non-Diabetic Patients With Nafld. The International Liver Congress; 11-15 April, Paris, France. 

F. Carli, M. Gaggini, C. Rosso, C. Saponaro, C. Barbieri, V.D. Latta, E. Buzzigoli, D. Ciociaro, M.L. Abate, M. Marietti, R. Younes, E. Bugianesi, A. Gastaldelli In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease. The International Liver Congress; 11-15 April, Paris, France. 

G. Svegliati-Baroni, I. Pierantonelli, R. Younes et al. Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients. The International Liver Congress; 11-15 April, Paris, France. 

B.Foglia, E.Morello, S.Sutti, S.Cannito, E.Novo, C.Bocca, S.Bruzzì, C.Rosso, R.Younes et al. Histidine rich glycoprotein as a hypoxia-inducible factor 2α-dependent pro-fibrogenic mediator in experimental nonalcoholicfatty liver disease. EASL NAFLD Summit - 20-22 September 2018 - Ginevra, Svizzera.

C.Rosso, R.Younes, Insulin secretion is directly related to NASH, fibrogenesis and fibrosis in Non-diabetic patients with Non-Alcoholic Fatty Liver Disease. EASL NAFLD Summit - 20-22 September 2018 - Ginevra, Svizzera.

R.Younes, O.Govaere Autoimmunity and NAFLD: clinical characteristics and long-term outcomes of patients with antinuclear antibody positivity. a longitudinal multicentric european study. EASL NAFLD Summit - 20-22 September 2018 - Ginevra, Svizzera.

LITMUS Kick-off Meeting and 1st General Assembly; 28th–29th November 2017, Sage Gateshead Conference Centre, Newcastle Upon Tyne, United Kingdom

British Obesity & Metabolic Surgery Society - Annual Scientific Meeting, 24-26 January 2018, Telford, United Kingdom

The International Liver Congress - European Association for the Study of the Liver - Annual Meeting, 11-15 April 2018, Paris, France

European Association for the Study of the Liver - NAFLD Summit, 20-22 September 2018, Geneva, Switzerland

EPoS - Elucidating Pathways of Steatohepatitis- Sixth Steering Committee; 15th–16th January 2018; Florence, Italy

Liver Biopsy in the Assessment of Medical Liver Disease;  Royal College of Pathologists, 23rd February 2018, London, United Kingdom

Litmus Histopathology Group - Kick-off Meeting - 24-25 February 2018, Bruxelles, Belgium

Introduction to Systematic Reviews in Health - 6th March 2018; Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, United Kingdom

6th Annual NAFLD Study Group Meeteing; 19-20 April 2018; Oxford, United Kingdom

Litmus - 2nd General Assembly; 18-19 September 2018; Geneva Switzerland